1617P Leucine-rich 2 glycoprotein 1 (LRG1) as potential systemic biomarker for response to neoadjuvant immune checkpoint blockade in stage III melanoma
Shizhen Chen, C.C.E. De Schrijver, H. Van Rossum, Theodora C. Linders, Lianne Hoeijmakers, M.W. Lucas, Esmée P. Hoefsmit, Irene L. M. Reijers, Petros Dimitriadis, B. van de Wiel, Karin E. de Visser, Astrid A.M. van der Veldt, Helena Eriksson, Geke A.P. Hospers, Richard A Scolyer, Karijn P.M. Suijkerbuijk, Ellen Kapiteijn, A.M. Menzies, G.V. Long, Christian U. Blank (2025). 1617P Leucine-rich 2 glycoprotein 1 (LRG1) as potential systemic biomarker for response to neoadjuvant immune checkpoint blockade in stage III melanoma. , 36, DOI: https://doi.org/10.1016/j.annonc.2025.08.2245.
